A new BET inhibitor review entitled "Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy" was recently published. 

https://www.future-science.com/doi/10.4155/fsoa-2018-0115

https://www.future-science.com/doi/pdf/10.4155/fsoa-2018-0115

As the title states, it is focused on cancer therapy. It does mention RVX-208 in the context of its ability to increase expression of Apo-AI and inhibit BRD3. It does list Zenith's ZEN-3694 and its clinical trials in its clinical trial table, but doesn't discuss beyond that. Overall, this is a nice article summarizing the clinical development of BET inhibitors in cancer, but not a good review of RVX-208/apabetalone or ZEN-3694

BearDownAZ

P.S. Thanks (again) to rndtbl for first posting on Investor Village